Doklady Biochemistry and Biophysics最新文献

{"title":"Semibalanus balanoides (L.) and Balanus crenatus Bruguière (Balanidae) Are Intermediate Hosts of Fimbriarioides intermedia (Fuhrmann, 1913) and Two Species of the Genus Microsomacanthus (Cestoda: Hymenolepidae), Parasites of Sea Ducks from the Atlantic Sector of the Arctic and Northern Pacific","authors":"K. V. Regel","doi":"10.1134/S1607672924701035","DOIUrl":"10.1134/S1607672924701035","url":null,"abstract":"<p>Metacestode infestation of <i>Semibalanus balanoides</i> (L., 1767) and <i>Balanus crenatus</i> Bruguiеre, 1789, collected in the Barents and White Seas and in the northern part of the Sea of Okhotsk in 2020 and 2021, respectively, was studied. A total of 313 <i>S. balanoides</i> from Mogilnaya Bay of Kildin Island (Barents Sea) and isolated mature wrinkled barnacles <i>B. crenatus</i>, two and four specimens from the Pechora Sea and Kandalaksha Bay of the White Sea, respectively, were examined in 2020. Metacestodes <i>Fimbriarioides intermedia</i> (Fuhrmann, 1913) (Cyclophyllidea, Hymenolepididae) were found in 1.0 ± 0.6% of <i>S. balanoides</i> in the Barents Sea with an invasion intensity (I. I.) of 2–5 specimens, and in one of two <i>B. crenatus</i> from the Pechora Sea (I. I. 15 specimens). For the first time, in both <i>B. crenatus</i> from the Pechora Sea, taken from the valves of the mussel <i>Mytilus edulis</i>, metacestodes <i>Microsomacanthus</i> sp. I (I. I. 13 and 20 specimens) with proboscis hooks 38–41 (39.4 ± 0.1) µm long and blades of 9.5–11 (10.7 ± 0.1) µm were obtained. One of four <i>B. crenatus</i> from the Kandalaksha Bay was infected with another <i>Microsomacanthus</i> sp. II (I. I. 19 specimens) with proboscis hooks 44.0–49.5 (45.7 ± 0.5) µm long and blades 14.0–16.0 (14.8 ± 0.07) µm long. A total of 362 <i>S. balanoides</i> were collected and dissected in Gizhiginskaya Bay of the northern part of the Sea of Okhotsk in 2021, of which 8.0 ± 1.4% were infected with <i>F. intermedia</i> metacestodes (I. I. 1–19 specimens). Study results of the infestation of <i>S. balanoides</i> on the Koni-Pyagin coast of the Sea of Okhotsk (according to the collections of 2006–2007) were supplemented and clarified. Description of metacestodes and the taxonomic affiliation of cysticercoids <i>Microsomacanthus</i> spp. are given.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":"518 1","pages":"313 - 324"},"PeriodicalIF":0.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141490402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular Characterization of Echinococcus canadensis (Cestoda, Taeniidae) in Wolf from the Kirov Region","authors":"O. A. Loginova,&nbsp;S. E. Spiridonov,&nbsp;O. V. Maslennikova,&nbsp;L. A. Bukina","doi":"10.1134/S1607672924701011","DOIUrl":"10.1134/S1607672924701011","url":null,"abstract":"<p>This work presents the results of studying the molecular characteristics of parasitic tapeworms <i>Echinococcus canadensis</i>. The helminths were discovered during the autopsy of a wolf (<i>Canis lupus</i> Linnaeus, 1758) killed by hunters in the Kirov oblast in 2021. A molecular phylogenetic study was performed by analyzing the sequence of a fragment of the first subunit of the mitochondrial cytochrome oxidase gene (<i>Cox</i>I). It was found that the detected echinococci belong to the G10 genotype of <i>E. canadensis</i>, which is common in wolves in the northern territories of the Holarctic. We discovered four positions at which the substitutions characteristic only of this genotype are revealed. A substitution at one of the positions that is characteristic exclusively for the representatives of the G10 genotype found in Russia and Finland was also discovered.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":"518 1","pages":"305 - 308"},"PeriodicalIF":0.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141490398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hyperleptinemia as a Marker of Various Phenotypes of Obesity and Overweight in Women with Rheumatoid Arthritis and Systemic Lupus Erythematosus","authors":"L.V. Kondratyeva,&nbsp;Yu. N. Gorbunova,&nbsp;T. A. Panafidina,&nbsp;T. V. Popkova","doi":"10.1134/S1607672924700893","DOIUrl":"10.1134/S1607672924700893","url":null,"abstract":"<p>The objective of the study was to identify different phenotypes of overweight in women with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) based on body mass index (BMI) and serum leptin levels, as well as to determine the frequencies of various metabolic disorders, hypertension, and cardiovascular complications (CVCs) in individual phenotypes. The study included 50 women with RA and 46 with SLE aged 18 to 65 years without a history of diabetes and fasting hyperglycemia. In all patients, the concentration of leptin was determined by ELISA, the concentration of insulin was determined by electrochemiluminescence analysis, and the HOMA-IR index was calculated. Hyperleptinemia was diagnosed at leptin concentrations &gt; 11.1 ng/mL; insulin resistance (IR), at HOMA-IR values ≥ 2.77. Three main phenotypes of overweight were distinguished: “classic” (BMI ≥ 25 kg/m² + hyperleptinemia), “healthy” (BMI ≥ 25 kg/m², without hyperleptinemia), “hidden” or “latent” (BMI &lt; 25 kg/m² + hyperleptinemia), as well as “normal weight” (BMI &lt; 25 kg/m², without hyperleptinemia). Patients with RA and SLE were similar in age (<i>p</i> = 0.4), disease duration (<i>p</i> = 0.2) and BMI (<i>p</i> = 0.5). Hyperleptinemia was found in 46% of women with RA and in 74% of women with SLE (<i>p</i> = 0.005), and IR was found in 10 and 22% of patients, respectively (<i>p</i> = 0.2). The “classic” phenotype of overweight was diagnosed in 30%, “healthy” in 8%, and “hidden” in 16% of cases with RA and in 44%, 0%, and 30% of cases with SLE, respectively. IR was found in 3% and hypertension in 6% of patients with “normal weight.” With the “classic” phenotype, IR (29%) and hypertension (66%) were more common than with “normal weight” (<i>p</i> &lt; 0.01 in all cases); with the “hidden” phenotype, significant differences were obtained only in hypertension frequency (45%; <i>p</i> = 0.0012), but not IR (18%). Three out of four women with a history of cardiovascular complications suffered from “classic” overweight, and one patient had a “normal weight.” In women with SLE up to 65 years of age, the frequency of hyperleptinemia, but not IR, is higher than in patients with RA. In both diseases, the “classic” overweight phenotype is most common. In RA, a “hidden” phenotype was detected less often than in SLE, at the same time, a “healthy” phenotype is not characteristic of SLE. The frequency of metabolic disorders and hypertension is low with the “normal weight” and “healthy” phenotype, high with the “classic” phenotype, and intermediate with the “hidden” phenotype.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":"517 1","pages":"182 - 194"},"PeriodicalIF":0.8,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141299600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Course of Uveitis in Patients with Ankylosing Spondylitis during the Interleukin17 Inhibitors Therapy","authors":"A. A. Godzenko,&nbsp;E. M. Agafonova,&nbsp;A. E. Dimitreva,&nbsp;I. Yu. Razumova,&nbsp;M. M. Urumova","doi":"10.1134/S1607672924700868","DOIUrl":"10.1134/S1607672924700868","url":null,"abstract":"<p>Biological disease-modifying antirheumatic drugs (bDMARDs) can have different effects on various clinical manifestations of ankylosing spondylitis (AS). Data on the effects of interleukin 17 inhibitors (IL17-i) on uveitis in AS continue to accumulate. Objective: to evaluate the effect of IL17-i therapy on the course of uveitis in AS. The study involved 73 patients with AS (New York criteria, 1984), who received IL17-i (57—secukinumab (SEC), 22—netakimab (NTK)) for at least 1 year. The average age of patients at the time of inclusion in the study was 41.93 ± 8.95 years, the average duration of AS was 10.75 ± 6.22 years. There were 40 men (56.7%) and 33 women (43.3%) among the patients. HLA-B27 was detected in 62/73 (85%), coxitis in 58 (79%), enthesitis in 63 (86.3%), peripheral arthritis in 57 (78%), psoriasis in 7 (9.5%), and inflammatory bowel disease (IBD) in 3 (4.1%) patients; in 6 (8.2%) patients, the disease started before the age of 16; 19 (26%) patients had at least one episode of uveitis during the course of the disease. The rates of uveitis was estimated by comparing the number of incidences per 100 patient-years before the start of bDMARDs therapy and during IL17-i using. The incidence rate of uveitis before the start of bDMARDs therapy for all patients was 8.3 per 100 pt-years (95% CI 0.065–0.107), during IL17-i therapy— 9.2 per 100 pt-years (95% CI 0.06–0.15), <i>p</i> = 0.72. The incidence rate of uveitis among patients who used SEC was 10.1 per 100 pt-years (95% CI 0.079–0.13) before the start of bDMARDs therapy and 9.4 per 100 pt-years (95% CI 0.05-0.15), <i>p</i> = 0.74 during SEC therapy. The incidence rate of uveitis among patients who used NTK was 4.8 per 100 pt-years (95% CI 0.028–0.08) before the start of bDMARDs therapy and 7.1 per 100 pt-years (95% CI 0.019–022), <i>p</i> = 0.3 during the NTK therapy. For patients with a history of uveitis, the incidence rate of uveitis was 22.5 per 100 pt-years (95% CI 0.18–0.28) before the start of therapy with bDMARDs and 29.1 per 100 pt-years (95% CI 0.18–0.43), <i>p</i> = 0.29 during IL17-i therapy. Occurrences of uveitis were observed in 4 of 57 patients (7%) during SEC therapy and in 1 of 25 (4%) patients during the NTK therapy. One case of new-onset uveitis was recorded during the using of SEC. There were no significant differences in the incidence rates of uveitis during IL17-i therapy compared with non-biological therapy. IL17-i therapy have not demonstrated a significant effect on the course of uveitis in AS in the study group.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":"517 1","pages":"166 - 172"},"PeriodicalIF":0.8,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141299640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the Possibility of Axial Psoriatic Arthritis Patients Meeting Classification Criteria for Axial Spondyloarthritis and Ankylosing Spondylitis","authors":"E. E. Gubar,&nbsp;T. V. Korotaeva,&nbsp;Yu. L. Korsakova,&nbsp;E. Yu. Loginova,&nbsp;A. V. Smirnov,&nbsp;A. V. Sukhinina,&nbsp;M. M. Urumova,&nbsp;S. I. Glukhova","doi":"10.1134/S160767292470087X","DOIUrl":"10.1134/S160767292470087X","url":null,"abstract":"<p>The objective of the study was to analyze whether axial psoriatic arthritis (axPsA) patients meet classification criteria for axial spondyloarthritis <b>(</b>axSpA) and ankylosing spondylitis (AS). A total of 104 patients (66 men and 38 women) with PsA according to CASPAR criteria were examined, all patients had back pain. Patients were evaluated for presence of inflammatory back pain (IBP) by ASAS criteria. Back pain not meeting the ASAS criteria was taken to be chronic back pain (chrBP). Patients underwent hands, feet and pelvis, cervical spine and lumbar spine X-rays. Erosions, osteolysis, and juxta-articular new bone formation were evaluated. Definite radiographic sacroiliitis (d-rSI) was defined as bilateral grade ≥ 2 or unilateral grade ≥ 3. Nineteen patients without d-rSI underwent sacroiliac joints MRI. Ninety-three patients underwent HLA B27 examination. The number of patients who met the criteria for axSpA (ASAS) and the modified New York (mNY) criteria for AS was determined. IBP was identified in 67 (64.4%) patients; chrBP, in 37 (35.6%) patients; 31 (29.8%) patient were of older age (over 40) at the onset of IBP/chrBP; 57 (58.8%) patients had d-rSI; 6 (31.6%) patients had MRI-SI; syndesmophytes were detected in 57 (58.8%) cases. Among 40 patients without d-rSI, 19 (47.5%) had syndesmophytes. In 38/97 (39.2%) patients d-rSI was detected along with syndesmophytes, while 19/97 (19.6%) patients had isolated d-rSI without spondylitis, and 19/97 (19.6%) patients had isolated syndesmophytes without d-rSI. HLA B27 was present in 28 (30.1%) cases. 51 (55.4%) patients met criteria for axSpA. Forty-one (44.6%) patients did not meet criteria for axSpA; however, 27 (65.9%) of them had syndesmophytes. Forty-eight (48.5%) PsA patients met mNY criteria for AS. Among these patients, a set of specific features was revealed: 18 (37.5%) had no IBP, 18 (37.5%) were of older age (over 40) at the onset of IBP/chrBP, 34 (70.8%) had dactylitis, 38 (79.2%) had erosive polyarthritis, 23 (48.8%) had juxta-articular new bone formation, 14 (30.2%) had osteolysis<b>,</b> 23 (48.9%) had “chunky” non-marginal syndesmophytes, and 40 (82.6%) had nail psoriasis; 28 (66.6%) patients were HLA-B27 negative. Forty-five percent of axPsA patients do not meet criteria for axSpA. Characteristic features have been identified to differentiate axPsA from AS.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":"517 1","pages":"173 - 181"},"PeriodicalIF":0.8,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141299599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Tolerability of Rituximab in the Treatment of Systemic Sclerosis","authors":"L. A. Garzanova,&nbsp;L. P. Ananyeva,&nbsp;O. A. Koneva,&nbsp;O. V. Desinova,&nbsp;M. N. Starovoytova,&nbsp;O. B. Ovsyannikova,&nbsp;R. U. Shayakhmetova,&nbsp;S. I. Glukhova","doi":"10.1134/S1607672924700856","DOIUrl":"10.1134/S1607672924700856","url":null,"abstract":"<p>Rituximab (RTX) has been used for the treatment of systemic sclerosis (SSс) for a long time and has shown good efficacy for skin fibrosis and interstitial lung disease (ILD). However, data on tolerability and long-term adverse events (AEs) during RTX therapy in SSc are insufficient. The objective of this study was to assess the tolerability and safety of RTX in patients with SSс in a long-term prospective follow-up. Our open-label prospective study included 151 SSс patients who received at least one RTX infusion. The mean age of the patients was 47.9 ± 13.4 years; the majority of them were women (83%). The mean disease duration was 6.4 ± 5.8 years. The mean follow-up period after the first RTX infusion was 5.6 ± 2.6 years (845.6 patient-years (PY)). All patients received RTX in addition to ongoing therapy with prednisone and/or immunosuppressants. AEs were assessed and recorded by a doctor in the hospital immediately after RTX infusion and then by patient’s reported outcome during the observation period. All causes of death were considered, regardless of treatment. A total of 85 AEs (56%) were registered, the overall incidence of AEs was 10/100 PY (95% confidence interval (CI) 8–12). The highest frequency of all AEs was observed in the first 2–6 months after the first course of RTX, however, these were mainly mild and moderate AEs (71%). The most frequent AEs were infections, they were observed in 40% of cases, with no serious opportunistic infections reported. The overall incidence of all infections was 7.1/100 PY (95% CI 5.5–9), serious infections—1.5/100 PY (95% CI 0.9–2.6). Infusion reactions occurred in 8% of patients. Other AEs were noted in 3% (0.6/100 PY, 95% CI 0.3–1.4). The overall incidence of serious AEs was 18%—3.2/100 PY (95% CI 2.2–4.6). There was a significant decrease of the immunoglobulin G (Ig G) during follow-up; however, its average values remained within normal limits. There were 17 deaths (11%) (2/100 PY, 95% CI 1.3–3.2). In most cases, patients died from the progression of the major organ failure, which arose before RTX treatment. In our study, the safety profile of RTX in SSс was assessed as favorable. It was similar to the AE profile in other autoimmune diseases treated with RTX. With an increase in the cumulative dose of RTX, no increase in AEs was observed. The mortality is comparable to the other severe autoimmune diseases in observational studies. Monitoring of IgG may be useful for patients with SSс on RTX therapy for early detection of the risk of developing infectious complications. RTX could be considered as a relatively safe drug for the complex therapy of SSс when standard therapy is ineffective or impossible.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":"517 1","pages":"156 - 165"},"PeriodicalIF":0.8,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141299601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diastolic Dysfunction of the Left and Right Ventricles in Patients with Calcium Pyrophosphate Crystal Storage Disease and Osteoarthritis","authors":"M. S. Eliseev,&nbsp;O. V. Zhelyabina,&nbsp;I. G. Kirillova,&nbsp;Yu. O. Korsakova,&nbsp;E. V. Cheremushkina","doi":"10.1134/S1607672924700881","DOIUrl":"10.1134/S1607672924700881","url":null,"abstract":"<p>The frequency and risk factors for the development of diastolic dysfunction (DD) in patients with CPPD and OA have not been studied. The objective of this study was to determine the frequency and identify risk factors (RF) for the development of DD of the left and right ventricles (LV and RV) in patients with calcium pyrophosphate crystal deposition disease (CPPD) and osteoarthritis (OA). The study included 26 patients with CPPD and with knee OA 18–65 years old, matched in age and gender, without cardiovascular disease (CVD), type 2 diabetes mellitus (DM2), and rheumatic diseases. Conventional risk factors (TRF) of CVD were assessed, and echocardiography was performed. The frequency of DD in patients with CPPD and OA was quite high and almost did not differ in both groups: it was detected in 19 patients, of which 11 (42%) had CPPD and 8 (31%) had OA (<i>p</i> = 0.39). Type 1 LV DD was detected in 10 (39%) patients with CPPD and in 8 (31%) with OA (<i>p</i> = 0.11); type 1RV DD was detected in 8 (31%) patients with CPPD and in 7 (27%) patients with OA (<i>p</i> = 0.17); and type 1 LV DD and RV DD was detected in 7 (27%) patients with both CPPD and with OA. DD types 2 and 3 were not detected in both groups. There were no differences in both groups in CV risk factors, except for the level of CRP (it was higher in CPPD) (<i>p</i> = 0.03). In the CPPD group, mean values of LV E/E' (<i>p</i> = 0.02), LVDT (<i>p</i> = 0.03), LVMI (<i>p</i> = 0.04) were significantly higher than in patients with OA. On the contrary, in patients with OA, indices EDV (<i>p</i> = 0.004) and TVC (<i>p</i> = 0.02) were higher. There were direct correlations between diastolic function indices and the following factors in CPPD: LVL, PWLV and PTH level (<i>r</i> = 0.7, <i>p</i> &lt;0.005), LV E' and PTH level (<i>r</i> = 0.7, <i>p</i> &lt; 0.005). Inverse correlations were found between the level of PTH and IS (<i>r</i> = –0.5, <i>p</i> &lt; 0.005), LVMI (<i>r</i> = –0.5, <i>p</i> &lt; 0.005), and the level of vitamin D and VDDT (<i>r</i> = –0.6, <i>p</i> &lt; 0.005). Direct correlations in OA were found between the level of CRP and PVAdiast (<i>r</i> = 0.6, <i>p</i> &lt; 0.005), and the level of sUA (<i>r</i> = 0.7, <i>p</i> &lt; 0.005), and the level of vitamin D and E/E'LV (<i>r</i> = 0.6, <i>p</i> &lt; 0.005). A high prevalence of LV and RV DD was found in patients with CPPD and OA. The presence of DD in CPPD was associated with lower vitamin D levels, and in OA with a higher level of sUA and a lower level of PTH.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":"517 1","pages":"148 - 155"},"PeriodicalIF":0.8,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141299597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Schnitzler’s Syndrome—Diagnostic Experience, Approaches to Therapy, and Patient Management according to a Multicenter Russian Cohort","authors":"S. O. Salugina,&nbsp;A. V. Torgashina,&nbsp;E. Yu. Borzova,&nbsp;V. V. Rameev,&nbsp;V. R. Gorodetsky,&nbsp;E. S. Fedorov,&nbsp;N. V. Muravyova","doi":"10.1134/S1607672924700923","DOIUrl":"10.1134/S1607672924700923","url":null,"abstract":"&lt;p&gt;The objectives of the study were to present the experience of diagnosis, management, and therapy with IL-1 inhibitors in patients with Schnitzler’s syndrome (SchS) according to a multicenter Russian cohort. An observational retrospective study for a 10-year period (2012–2022) involved 17 patients with SchS who were admitted to the hospital or were observed on an outpatient basis (eight women and nine men). The diagnosis of all of them corresponded to the Strasbourg diagnostic criteria. The age of patients ranged from 25 to 81 years (Me 53[46; 56]). The age at the time of the onset of the disease ranged from 20 to 72 years (Me 46[39; 54]), the duration of the disease before diagnosis ranged from 1 to 35 years (Me 6.5[3; 6]), in three patients it exceeded 10 years, in the rest it ranged from 1 to 8 years. Infectious and lymphoproliferative diseases, monogenic AIDs (CAPS, TRAPS, and HIDS) were excluded from all patients at the prehospital stage. The referral diagnosis for all of them was Still 's disease in adults. Clinical manifestations of the disease in all patients included fatigue, lethargy, fatigue, rash, and fever. In all patients, skin elements were urticular and were accompanied by itching in 6 (37.5%) patients. Bone pain was observed in 12 (70.6%) patients; arthralgias, in 16 (94.1%); arthritis, in 9 (52.9%); myalgia, in 7 (41.2%); and weight loss, in 4 (23.5%). Lymphadenopathy was detected in 6 (35.3%) patients; enlarged liver, in 6 (35.3%); pericarditis, in 4 (23.5%); angioedema, in 6 (35.3); redness and dryness in the eyes, in 3 (17.6%); sore throat, in 2 (11.8%); abdominal pain, in 1 (5.9%), distal polyneuropathy, in 2 (11.8%); paraesthesia, in 1 (5.9%); and chondritis of the auricles, in 1 (5.9%). Monoclonal gammopathy was detected in all patients with a secretion level of 2.9–15.1 g/L: IgMk (&lt;i&gt;n&lt;/i&gt; = 10, 64.7%), less often IgMλ (&lt;i&gt;n&lt;/i&gt; = 2), IgGk (&lt;i&gt;n&lt;/i&gt; = 2), IgGλ (&lt;i&gt;n&lt;/i&gt; = 1), and IgAλ (&lt;i&gt;n&lt;/i&gt; = 1). Ben-Jones protein was not detected in any of them. All patients had an increased level of ESR and CRP. Before inclusion in the study, 16 patients received GCs (94.1%) with a temporary effect that disappeared with dose reduction or cancellation. Seven patients received cDMARDs, including methotrexate (5), hydroxychloroquine (2), and cyclophosphamide (1). All patients received NSAIDs and antihistamines, as well as biologics, including the anti-B-cell drug rituximab (1), monoclonal ABs to IgE omalizumab (2, 1 without effect and 1 with partial effect), IL-1i canakinumab (&lt;i&gt;n&lt;/i&gt; = 10, 58.8%) subcutaneously once every 8 weeks, and anakinra (&lt;i&gt;n&lt;/i&gt; = 4, 23.5%) subcutaneously daily. The duration of taking anakinra, which was prescribed in the test mode, ranged from 1 week to 2.5 months with a further switch to canakinumab in 3 patients. The duration of taking canakinumab at the time of analysis ranged from 7 months to 8 years. Against the background of treatment with IL-1i, 10 out of 11 (90.9%) patients received a complete resp","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":"517 1","pages":"214 - 227"},"PeriodicalIF":0.8,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141299602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Significance of Antibodies to DFS70 in Immunoinflammatory Rheumatic Diseases","authors":"T. A. Panafidina,&nbsp;Zh. G. Verizhnikova,&nbsp;A. S. Avdeeva,&nbsp;T. V. Popkova,&nbsp;E. L. Nasonov","doi":"10.1134/S1607672924700911","DOIUrl":"10.1134/S1607672924700911","url":null,"abstract":"<p>The relevance of the problem of immunoinflammatory rheumatic diseases (IIRD) for modern medicine is determined by their high prevalence in the population, the difficulty of early diagnosis, the rapid development of disability and poor life prognosis. Recent data on the significance of anti-DFS70 have opened up new possibilities for optimizing the step-by-step diagnosis of IIRD. The detection of these antibodies can help in the interpretation of a positive result for antinuclear antibodies (ANA) by indirect immunofluorescence assay on HEp-2 cells (IIFA-HEp-2) in the absence of autoantibodies specific for IIRD. Detection of anti-DFS70 in antinuclear factor (ANF) seropositive patients without clinical and/or serological markers characteristic of a certain disease from the IIRD group can be considered as a potential marker that excludes this group of diseases.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":"517 1","pages":"207 - 213"},"PeriodicalIF":0.8,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141299639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Use of “Acellbia”—A Biosimilar of Rituximab in Systemic Sclerosis","authors":"L. P. Ananyeva,&nbsp;L. A. Garzanova,&nbsp;O. V. Desinova,&nbsp;R. U. Shayakhmetova,&nbsp;M. N. Starovoitova,&nbsp;O. A. Koneva,&nbsp;O. B. Ovsyannikova,&nbsp;S. I. Glukhova,&nbsp;E. L. Nasonov","doi":"10.1134/S1607672924700844","DOIUrl":"10.1134/S1607672924700844","url":null,"abstract":"<p>The possibilities of modern therapy for systemic sclerosis (SSc) remains limited, since most of the used drugs do not have a disease-modifying effect. This encourages the study of new approaches that potentially affect the fundamental pathological processes underlying the disease. One example is anti-B-cell therapy, in particular rituximab (RTX). Until now RTX does not have a registration for the treatment of SSc, but there is a large positive experience of its use, which is reflected in recent meta-analyses and clinical recommendations. Complicated and expensive methods for obtaining genetically engineered biological drugs (biologics) have contributed to the emergence of more accessible biosimilars, one of which is the RTX biosimilar, Acellbia (Biocad, Russian Federation). The ‘‘biosimilar’’ versions of RTX might reduce the cost of therapy and increase patients accessibility to this treatment option. The RTX biosimilar Acellbia (ACB) has received approval in Russian Federation in 2014 for all indications held by reference RTX (including rheumatoid arthritis and ANCA-associated vasculitis).</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":"517 1","pages":"140 - 147"},"PeriodicalIF":0.8,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141299603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}